Testing Menu

New discoveries are increasing the number of biomarker/drug associations at an unprecedented rate. It is more important than ever for cancer patients to have comprehensive molecular testing on their tumors. 

Comprehensive Tumor Profiling

Caris molecular profiling utilizes a comprehensive approach to assess DNA, RNA and proteins to reveal a molecular blueprint to guide more precise and individualized treatment decisions from among 75+ FDA-approved therapies.

icon_DNA

DNA

Whole Exome Sequencing (Mutations, Indels, Copy Number Alterations & Karyotyping)
icon_RNA

RNA

Whole Transcriptome Sequencing (Fusions, Variant Transcripts & Gene Expression)
icon_Protein

Protein

Immunohistochemistry
(Tumor-expressed antigens)

Technical Specifications

Sufficient tumor content (>20% tumor nuclei) must be present to complete all analysis. If you have questions, please contact Customer Support at (888) 979-8669.

FFPE/SLIDE TISSUE

Tumor content: >20% tumor nuclei


Paraffin Block (Preferred)

Formalin fixed tissue block (including core-needle biopsies, fine-needle aspirates or malignant fluid)


Unstained Slides

25 slides

FRESH TISSUE

10% neutral buffered formalin


Four to six (4-6) biopsies with 18 gauge needle preferred


Six to ten (6-10) biopsies with 22 needle accepted

Caris Report Specs


Approach
Multi-Omic Biomarker Analysis


Biological Coverage
DNA  RNA  Protein


Variant Coverage
Somatic


Technology
NGS (WES & WTS)  IHC  ISH  PyroSeq


Genes | Depth/Read
22,000 | 800x WES/23Mx WTS


Whole Exome Sequencing (WES) DNA
SNV  INDEL  CNA  Karyotyping


Whole Transcriptome Sequencing (WTS) RNA
Fusion      Variant Transcript     Gene Expression


Genomic Signatures
HRD*  gLOH MSI  TMB


Other

HLA Genotype*


Enrichment Method
Microdissection


Result Rate
>95%


Turnaround Time
10-14 Days


Specimen Quantity
20% Tumor (NGS) | 1 Slide per IHC/ISH

*Not available in all locations.

Caris Molecular Profiling Menu by Region

international-caris-sm-ol-co.svg

International & US

Review and download the Caris molecular profiling testing menu for US and International cases.
new-york-caris-sm-ol-co.svg

New York

Review and download the Caris molecular profiling testing menu for New York state cases.
europe-caris-sm-ol-co.svg

European Union (EU)

Review and download the Caris molecular profiling testing menu for European cases.

Please complete the form below to have a Caris Scientific Rep (Medical Science Liaison) contact you directly.

"*" indicates required fields

Name*
Preferred contact method*

Biomarker Analysis by Tumor Type

The information below details the biomarkers analyzed by technology for the tumor type submitted. Tests may vary if insufficient tumor samples are submitted.

Looking for a Specific Gene?

Use our full gene search to verify that it is included in Caris profiling, or browse the list of genes most commonly associated with cancer.

Search Genes >

General Profile Menu (see above links for market specific menus)

All Biomarker Analysis includes:

Whole Exome Sequencing (WES)

DNA
Genomic
Signatures
Others
Point Mutations
Indels
Copy Number Alterations
Karyotyping
HPV 16 and 18
HRD*
gLOH
MSI
TMB
HLA*
*Not available in all locations.

Whole Transcriptome Sequencing (WTS)

RNA
Fusion Analysis
Variant Transcripts
Gene Expression

Additional Testing:

Select tumor type to see specific tests to be performed.

Tumor Type:
No tumor selected

Additional Information:

  • Caris applies the appropriate tumor-specific customizations standard with every order.
  • In certain instances, some biomarkers or genes ordered individually will not associate with commercially available cancer therapies or clinical trials.
  • For PD-L1 IHC testing, Dako antibodies 22c3, 28-8 and antibodies SP-142 and SP263 are used as appropriate.
  • For certain patients, HER2 testing is performed by Chromogenic in situ Hybridization, in addition to Next-Generation Sequencing.

REFLEX TESTING MENU >

Order Profiling

Place an order today for a comprehensive, personalized Caris profiling report.